Sun Pharma, the largest pharmaceutical company in India, has announced its acquisition of Checkpoint Therapeutics for $355 million. This move is aimed at bolstering Sun Pharma’s specialty portfolio, particularly with the addition of UNLOXCYT, an FDA-approved treatment for advanced skin cancer. By acquiring Checkpoint Therapeutics, Sun Pharma is looking to strengthen its global presence in oncology treatments.